Levels of Antinuclear and Anti-double Stranded Antibodies in Sera of Breast Cancer Patients doi.org/10.26538/tjnpr/v5i1.6

Abstract

Antinuclear antibodies (ANAs) and anti-double stranded deoxyribonucleic acid antibodies (ADSADs) are autoantibodies that have been linked to biomarkers of systemic autoimmune diseases. Although their involvement in relation to breast cancer is yet to be examined. Therefore, this study evaluated the serum  concentration of ANAs and ADSDAs in breast cancer patients, with a view to finding diagnostic biomarkers. One hundred female patients with breast cancer which were recently diagnosed depending on histopathology and hormonal receptor criteria by an oncologist, and another twenty-five females as healthy control group were recruited for the study. Direct interview of the female patients and healthy (control) group was conducted in addition to the information from patients’ registration records in the hospital. An aliquot of 5 mL of intravenous blood was collected from each subject to recover serum samples after centrifugation. An enzyme-linked immunosorbent assay (ELISA) was used to measure the concentrations of ANAs and ADSADs in the sera. The mean age of breast cancer patients was 55.60 years, while that of the healthy control group was 56.76 years.  here was a highly significant (P < 0.05) association between ANA of breast cancer patients and grade, as well as stage (MCP < 0.01). On the contrary, the concentration of ADSADs was showing no significant association with the grade (MCP > 0.05) and stage (MCP > 0.05) of breast cancer patients. Conclusively, our findings suggest the use of ANA as a diagnostic biomarker for breast cancer patients.